Skip to main content
Fig. 2 | BMC Research Notes

Fig. 2

From: Pharmacological profiling of a dual FAK/IGF-1R kinase inhibitor TAE226 in cellular and in vivo tumor models

Fig. 2

Effects of TAE226 on signaling pathways and tumor growth in 4T1 models. a Effects of TAE226 on phosphorylation of FAK at Y397, Akt at S473 and ERK1/2 in 4T1 cells treated for 1 h. b Effects of TAE226 on phosphorylation of FAK at Y397, Akt at S473 and ERK1/2 in 4T1 tumors. Tumor samples were collected 3 h after administration of TAE226 at doses of 10, 30 and 100 mg/kg. Two or three animals were used for each group and each lane represents an individual animal. Asterisk indicates degraded phospho-FAK in 4T1 tumor probably due to insufficient inhibition of non-specific protease inhibition. c Effects of TAE226 on 4T1 tumor growth (n = 8). Tumor volume was calculated according to the formula: length × width2/2. d Effects of TAE226 on metastasis. Values are expressed by mean ± SEM. Doxorubicin was administered intravenously once weekly. Values are expressed by mean ± SEM

Back to article page